Europe
Across the globe, pharma companies are making an impact. Last week BioSpace launched the first of a weekly roundup of international biotech and pharma news. Here’s the latest edition.
GlaxoSmithKline has been in the midst of a significant reshaping to focus on pharmaceuticals, particularly a renewed interest in oncology treatments. As a result, the company has made some cuts to its pipeline, including six quietly announced this morning in the company’s year-end report.
Merck KGaA, Darmstadt, Germany and GlaxoSmithKline forged an agreement to develop an immunotherapy for difficult to treat cancers that could be worth up to $4 billion. Following the announcement, a subsidiary of Merck KGaA announced plans to expand its Billerica, Mass. R&D facility.
MorphoSys AG announced the appointment of David R. Trexler as President and member of the Board of Directors of MorphoSys US Inc., effective February 6, 2019.
Ingenza is pleased to announce that University of Plymouth spin-out Amprologix, in which it has a stake, has been awarded a £1.2 million contract from the UK Department of Health and Social Care to accelerate the development and scale up its lead antibiotic candidate, Epidermicin NI01.
Syrris provides award-winning chemistry products to a range of research and development chemists and engineers, including Xeros Technology Group, a company specializing in novel and sustainable polymer solutions to advance the commercial laundry industry.
China represents the largest market for baby food globally
Cash position of €207.2 million as of December 31, 2018, compared to €273.8 million as of December 31, 2017
Eli Lilly and Co. has licensed 2G UNic technology from Leiden, the Netherlands-based ProteoNic Biotechnology BV. The tech is used to improve recombinant protein production. No financial details were disclosed.
Paris-based Sanofi announced positive results from its pivotal Phase III trial of isatuximab in patients with relapsed/refractory multiple myeloma.
PRESS RELEASES